Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 11, 2021

View Archived Issues

MGTA-117 confers better survival in preclinical models of AML

NanoViricides reports animal safety data on broad-spectrum anti-coronavirus drug candidate NV-CoV-2

Careful with that BBB

Janssen initiates phase II portion of first-in-human trial of talquetamab

Enrollment ongoing in phase III study of LNP-023 in adults with PNH with residual anemia

mNb6-tri, a novel potent trivalent nanobody against SARS-CoV-2

Panbela provides updates regarding its development of SBP-101

Updates on clinical development of the Parkinson's disease candidate YTX-7739

Silverback Therapeutics patents TGFR-1 inhibitors

Korean investigators disclose tubulin polymerization inhibitors

Kinnate Biopharma synthesizes new CDK inhibitors

French researchers describe PD-1/PD-L1 interaction inhibitors

New bispecific antibodies presented by WuXi Biologics

Phase III trials of ziritaxestat in IPF discontinued

Celularity presents preliminary phase I data on CYNK-001 in patients with AML with MRD

FDA clears IND for phase I/II trial of PhageBank in prosthetic joint infections

New phase III study evaluates AZD-9833 with palbociclib in ER-positive HER2-negative breast cancer

Mesoblast reports phase III data on rexlemestrocel-L for chronic low back pain

Artios initiates phase I/IIa trial of ATR inhibitor ART-0380 in advanced or metastatic solid tumors

Preliminary first-in-human data for NEXI-001 shows promise for patients with relapsed AML

Early signs of Batten disease stabilization seen with gene therapy AT-GTX-502

IND cleared in U.S. for phase II study of izokibep in ankylosing spondylitis

Dependencies join mutations in precision medicine search

Popular Stories

News in brief
BioWorld Asia
BioWorld Asia briefs for April 28, 2026
Chinese biotechs gain leverage as partners in dealmaking
BioWorld
China’s biotech ecosystem has crossed an inflection point, and Chinese biotechs are gaining leverage in dealmaking, executives from multinational companies said...
Bio Korea 2026 kicks off with spotlight on oligonucleotides
BioWorld
Three decades of trial-and-error, and the resulting safety data, in the oligonucleotide-based therapeutic space have paved way for the present-day innovations and...
Roche identifies new TREM2 agonists
BioWorld Science
F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. have prepared and tested new compounds acting as triggering receptor expressed on myeloid cells 2 (TREM2)...
Plasticity, properly parsed, provides psychiatric platform
BioWorld
If Benjamin Braddock, of The Graduate fame, were a young neuroscientist in the 21st century instead of a liberal arts graduate in 1967, the advice he received...